User:Mr. Ibrahem/Evinacumab
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Human |
| Target | Angiopoietin-like 3 (ANGPTL3) |
| Clinical data | |
| Trade names | Evkeeza |
| Other names | REGN1500, evinacumab-dgnb |
| AHFS/Drugs.com | Monograph |
| License data |
|
| Routes of administration | Intravenous |
| Legal status | |
| Legal status | |
| Chemical and physical data | |
| Formula | C6480H9992N1716O2042S46 |
| Molar mass | 146083.95 g·mol−1 |
Evinacumab, sold under the brand name Evkeeza, is a medication used to treat homozygous familial hypercholesterolemia (HoFH).[1] It is used in those who are at least 12 years old; however, effects on heart disease and life expectancy is unclear as of 2022.[1] It is given by injection into a vein.[1]
Common side effects include the influenza-like illness, dizziness, runny nose, and nausea.[1] Other side effects may include anaphylaxis.[1] Use in pregnancy may harm the baby.[1] It is a monoclonal antibody that binds to and blocks angiopoietin-like protein 3 (ANGPTL3), resulting in faster break down of fats.[1][3]
Evinacumab was approved for medical use in the United States and Europe in 2021.[1][3] In the United States it costs about 450,000 USD per year as of 2022.[4]
References[edit]
- ^ a b c d e f g h i j k l "Evkeeza- evinacumab injection, solution, concentrate". DailyMed. Archived from the original on 14 September 2021. Retrieved 14 September 2021.
- ^ "FDA approves add-on therapy for patients with genetic form of severely". U.S. Food and Drug Administration (FDA). 11 February 2021. Archived from the original on 12 February 2021. Retrieved 12 February 2021.
This article incorporates text from this source, which is in the public domain.
- ^ a b c "Evkeeza EPAR". European Medicines Agency (EMA). 21 April 2021. Archived from the original on 19 December 2021. Retrieved 18 December 2021.
- ^ "Evinacumab". SPS - Specialist Pharmacy Service. 21 September 2018. Archived from the original on 3 March 2022. Retrieved 31 October 2022.
